Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2018’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)

- The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects

- The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Arch Biopartners Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co ...

Allena Pharmaceuticals Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Arch Biopartners Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Cellmid Ltd

Corvidia Therapeutics Inc

DiaMedica Therapeutics Inc

Dimerix Bioscience Pty Ltd

DURECT Corp

Evotec AG

GNI Group Ltd

KBP BioSciences Co Ltd

Klotho Therapeutics Inc

Nash Pharmaceuticals Inc

Novartis AG

OPKO Health Inc

Opsidio LLC

Otsuka Holdings Co Ltd

Prolong Pharmaceuticals LLC

ProMetic Life Sciences Inc

Reata Pharmaceuticals Inc

Resverlogix Corp

Sanwa Kagaku Kenkyusho Co Ltd

Sarfez Pharmaceuticals Inc

Sphaera Pharma Pte Ltd

Taisho Pharmaceutical Holdings Co Ltd

Theravance Biopharma Inc

Unity Biotechnology Inc

Vascular BioSciences

VESSL Therapeutics Ltd

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Chronic Kidney Disease (Chronic Renal Failure) - Overview 6

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development ...

Table of Contents

Table of Contents 2

Introduction 5

Chronic Kidney Disease (Chronic Renal Failure) - Overview 6

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development 7

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 17

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 27

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles 45

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 199

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 202

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 203

Appendix 215

List of Tables

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2018

Number of Products under Development by Companies, H2 ...

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nash Pharmaceuticals Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pte Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Theravance Biopharma Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2018 (Contd..2), H2 2018

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2018

Number of Products under Development by Companies, H2 ...

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports